Pfizer Corporation

Other

Robert James Crook

Alan John Pettman

Bernard Joseph Banks

Stephen Paul Gibson

Graham Lunn

Alan Stobie

Elisabeth Colette Louise Gautier

David Charles Waite

Robert Walton

Lee Terence Boulton

Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances. 

3-azabicyclo[3.1.0]hexane derivatives useful in therapy

The invention provides a process for the production of a compound of formula (A), or a pharmaceutically acceptable salt or solvate thereof,wherein R, R, R, and Rare as defined herein.

Process for the production of quinazolines

The present invention relates to a mutual prodrug of amlodipine and atorvastatin, pharmaceutically acceptable acid addition salts thereof, pharmaceutical compositions thereof and the use of said prodrug and its salts in the manufacture of medicaments for the treatment of atherosclerosis, angina pectoris, combined hypertension and hyperlipidaemia and the management of cardiac risk.

Mutual prodrug of amlodipine and atorvastatin

This invention relates to 2,3(1H,4H)-quinoxalinedione derivatives which are selective antagonists of N-methyl-D-aspartate receptors. More particularly, this invention relates to 5-triazolyl-2,3(1H,4H)-quinoxalinedione derivatives and to the preparation of, compositions containing, and the uses of, such derivatives. It also relates to a method for treating acute neurodegeneration disorders and chronic neurological disorders.

Quinoxalinediones

Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances.

Growing community of inventors

Kent, United Kingdom

Robert James Crook